THE AUSTRIAN CENTRE
OF INDUSTRIAL BIOTECHNOLOGY

acib is an international competence centre, developing new, environmentally friendly, economically and technically advanced processes for the biotechnological, pharmaceutical and chemical industry – all of them modelled on nature. acib is bridging the gap between academic research and producing industry. The big advantage for acib partner organisations is the possibility to translate scientific results into concrete processes and product by using scientific know-how, academic infrastructure or industrial networks. Our platform offers tailor-made solutions for our stakeholders from Academia, Industry and Investors.

 LATEST BLOG ARTICLES
  • Key for citric acid production discovered
  • Young scientists and the continuous approach of biotechnological production
  • In need of data – paving the way for industry 4.0
  • The 4 letters of Chinese Hamster
  • Enhanced enzymes for safer and faster drug development
  • Targeting cancer
  • Myths and facts about crowdinvesting
  • Den Enzos auf der Spur
  • How sugar beets sweeten our life
  • P450 CYPs and Capsaicin –  a hot new way of simulating drug-metabolism outside the human body
  • Key for citric acid production discovered

    The responsible transport gene that allows the production of lemon acid in large quantities was recently discovered. A breakthrough!

    Read more

  • Young scientists and the continuous approach of biotechnological production

    Bioproducts for various applications such as pharmaceuticals, cosmetics, nutrients or industrial enzymes are manufactured with biotechnological methods; microorganisms or immortalized cell lines are the vehicles for production. Due to the long development times such products, especially in the area of pharmaceuticals, are often very expensive. The question is how can we make the production process of bioproducts faster, cheaper and fit for the future.

    Read more

  • In need of data – paving the way for industry 4.0

    What lies behind the data shown on a LCD screen? What do the numbers express and moreover, can we trust them? Is the value displayed correct and can we deduct the right conclusion to set a responsive course of action?

    Read more

  • The 4 letters of Chinese Hamster

    Did you know that nowadays bacteria and mammalian cells, especially hamster cells, produce a wide range of drugs? And who tells them to do so? The answer is the four-letter code of DNA. Biotechnologists spend a lot of time to explore natural DNA sequences of different organisms for production. The Chinese Hamster is a mammalian system and suits well for cell factories because of its similarity to human cells. However, for a long time the knowledge about the hamster DNA sequence had many gaps that needed to be investigated.

    Read more

  • Enhanced enzymes for safer and faster drug development

    Co-author: Martin Walpot

    In the development of drugs and pharmaceutical compounds, expensive tests are necessary, to know, which metabolic by-products and side-effects could emerge and to ensure that drugs are working effectively and in a safe manner. Human-like CYP450 enzymes, which mimic the same activities happening in the human body, are new, excellent biocatalytic tools to screen side effects outside the human body. They also enable the timely production of reasonable amounts of active pharmaceutical ingredients. Used as biocatalysts in industrial applications, new CYP450 enzymes, developed in the EU-project ROBOX, have the potential to speed up drug development, enhance pharmaceutical safety and to innovate chemical markets such as flavour-, fragrance or food industries.

    Read more

  • Targeting cancer

    The complex tumour structure makes the treatment of breast cancer a medical challenge. A promising, novel selenium-based breast cancer nanoparticle therapy, which is topic of the EU-project Neosetac, could change that: It has proved to boost the active agent delivery and assure it’s active only in the target tissue while also bringing the suggestion of reduced side effects. The project findings are expected to increase the efficiency of future chemotherapies and prevent recurrence of the cancer after complete remission.

    Read more

  • Myths and facts about crowdinvesting

    In our previous article Insights into crowdfunding the concept of crowdfunding was explained while the following article focuses on investment. Crowdinvesting is not a miracle. However, there are a few myths due to misinformation about some basic principles and due to still changing legal provisions of this new financial instrument. Some of these myths are related to the expectations about the parties involved.  The following facts are supposed to dismantle the myths of crowdinvesting.

    Read more

  • Den Enzos auf der Spur

    Auf das Abenteuer Forschung haben sich im Rahmen des Projektes „Enzyme im Alltag“ neun Schulklassen aus Volksschulen, NMS und Gymnasien eingelassen. Gemeinsam mit Wissenschaftlerinnen und Wissenschaftlern vom acib und der TU Graz und den Firmenpartnern Bisy, Qualizyme und QPS erkundeten die Kinder und ihre Lehrkräfte innerhalb von 2 Jahren die enorme Vielfalt enzymatischer Abläufe und entdeckten sie im täglichen Leben.

    Read more

  • How sugar beets sweeten our life

    Sugar is not only a widely used food ingredient but can also be used as possible starting point for high-added-value products. The European research consortium of CARBAFIN explores different ways to make use of sugar beet biomass: the sugar components glucose and fructose are starting points for the production of important ingredients for not only food/feed but also cosmetics. Besides, fructose can be further converted to a platform chemical, which is applied to the production of bioplastics, biofuels or biopolymers, as well as resins. In other words, CARBAFIN people sweeten our lives!

    Read more

  • P450 CYPs and Capsaicin – a hot new way of simulating drug-metabolism outside the human body

    Have you ever wondered, why it often takes many years until a new drug is available at your local pharmacy? One of the reasons is that the pharmaceutical industry wants to make sure that the drug is not only effective but also doesn’t produce toxic breakdown products that lead to undesireable side effects. Therefore, many time-consuming and not seldomly expensive tests are required to know precisely, which possible metabolic by-products could emerge. In a next step, the industry is producing such derivates to test them thoroughly for their side-effects, ensuring one goal: the patients health and wellbeing. 

    Read more

COMPANY PROFILE AND OWNERS

acib is an industrially oriented private limited company with a non-profit orientation. It is publicly owned by:

K2 RESEARCH CENTRE

acib is funded as a K2 research centre in the framework of FFG COMET funding (Competence Centres for Excellent Technologies) by BMVIT, BMWF, and the provinces of Styria, Vienna, Lower Austria and Tyrol. The COMET programme is processed via FFG. 18 scientific partners are involved in the implementation of the acib COMET programme, which is co-funded by 53 industrial partners.

More about COMET



Innovations from Nature 1
Innovations from Nature 4
Innovations from Nature 5
Innovations from Nature 2
Innovations from Nature 3
Innovations from Nature 6